Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised VEF AB (publ) in connection with the listing of the company’s ordinary shares on Nasdaq Stockholm’s Main Market
Mandate

Vinge has advised VEF AB (publ) in connection with the listing of the company’s ordinary shares on Nasdaq Stockholm’s Main Market

June 03, 2022 Capital Markets and Public M&A Corporate Tax

Vinge has advised VEF AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s Main Market. The prospectus was published on 30 May 2022 and the trading on Nasdaq Stockholm commenced on 1 June 2022.

VEF is an investment company that invests in growth stage private fintech companies. VEF focuses on scale emerging markets and invests across all areas of financial services inclusive of payments, credit, mobile money and wealth advisors.

Vinge’s team has primarily consisted of Jesper Schönbeck, Joel Wahlberg, Emma Brolund, Anna Svensson and Johannes Akyol (Capital Markets and Public M&A) and Victor Ericsson and Emelie Svanberg (Corporate Tax).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026